Metfendrazine
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Monkbot (talk | contribs) at 07:20, 7 December 2020 (Task 18 (cosmetic): eval 2 templates: del empty params (1×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 07:20, 7 December 2020 by Monkbot (talk | contribs) (Task 18 (cosmetic): eval 2 templates: del empty params (1×);)
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H16N2 |
| Molar mass | 164.252 g·mol−1 |
Metfendrazine (HM-11, MO-482), also known as methphendrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class.[1][2] It was investigated as an antidepressant, but was never marketed.
See also
References
- ^ Miquel, J.; Mijan, C. D. (1962). "Metfendrazine, a new inhibitor of monoamine oxidase". Arch. Inst. Farmacol. Exp. (Madrid). 14: 47–59.
- ^ Kothari NJ, Saunders JC, Kline NS, Griffen JA (October 1960). "A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics". The American Journal of Psychiatry. 117: 358–60. doi:10.1176/ajp.117.4.358. PMID 13753478.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |